# Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

> **NCT00648037** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Hodgkin's Disease
- Leukemia
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00648037
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2016-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648037, "Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00648037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*